Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue 1, 2000, Pages 25-34

  Huber, J ^a   Foidart, J M ^b,g   Wuttke, W ^c   Merki Feld, G S ^d   The, H S ^e   Gerlinger, C ^f   Schellschmidt, I ^f   Heithecker, R ^f  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d Department of Women's Health ^*  (Switzerland)

^e Location Alkmaar   (Netherlands)

^f BAYER PHARMA AG   (Germany)

^g Centre Hospitalier Regional de La Citadelle   (Belgium)

Author keywords

Antiandrogenic effect; Antimineralocorticoid effect; Drospirenone; Natural progesterone; Oral contraceptive; Tolerability; Weight loss

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; GESTAGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; MULTICENTER STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; WEIGHT REDUCTION;

EID: 0034113938     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180008500375     Document Type: Article

References (9)

1. 1. Rosenberg M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82
2. 2. Woods ER, Grace E. Havens KK, et al. Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. Am J Obstet Gynecol 1992;166:901-7
3. 3. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone, a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995;51:99-110
4. 4. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
5. 5. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-42
6. 6. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21
7. 7. Rosenbaum P, Schmidt W, Helmerhorst FM, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000;5:16-24
8. 8. Burke BM, Cunliffe WJ. The assessment of acne vulgaris -the Leeds technique. Br J Dermatol 1984;111:83-92
9. 9. Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning and sterilization among 1466 women. Contraception 1999;59:277-86